Emerging New Concepts of Degrader Technologies
Yu Ding,Yiyan Fei,Boxun Lu
DOI: https://doi.org/10.1016/j.tips.2020.04.005
IF: 17.638
2020-01-01
Trends in Pharmacological Sciences
Abstract:Selective degradation of pathogenic proteins is a promising strategy to drug 'undruggable' targets.Established degrader technologies such as PROTAC are extremely promising but still have limitations.The lysosome is a major degradation pathway utilized by cells to degrade extracellular and intracellular content.New technologies such as LYTAC, AUTAC, and ATTEC may have potential applications in several diseases by exploiting the lysosome for targeted degradation. Traditional drug discovery focuses on identifying direct inhibitors of target proteins. This typically relies on a measurable biochemical readout and accessible binding sites whose occupancy influences the function of the target protein. These requirements preclude many disease-causing proteins from being 'druggable' targets, and these proteins are categorized as 'undruggable'. The proteolysis-targeting chimera (PROTAC) technology provides powerful tools to degrade these undruggable targets and has become a promising approach for drug discovery. However, the PROTAC technology has some limitations, and emerging new degrader technologies may greatly broaden the spectrum of targets that could be selectively degraded by harnessing a second major degradation pathway in cells. We review key emerging technologies that exploit the lysosomal degradation pathway and discuss their potential applications and limitations. Traditional drug discovery focuses on identifying direct inhibitors of target proteins. This typically relies on a measurable biochemical readout and accessible binding sites whose occupancy influences the function of the target protein. These requirements preclude many disease-causing proteins from being 'druggable' targets, and these proteins are categorized as 'undruggable'. The proteolysis-targeting chimera (PROTAC) technology provides powerful tools to degrade these undruggable targets and has become a promising approach for drug discovery. However, the PROTAC technology has some limitations, and emerging new degrader technologies may greatly broaden the spectrum of targets that could be selectively degraded by harnessing a second major degradation pathway in cells. We review key emerging technologies that exploit the lysosomal degradation pathway and discuss their potential applications and limitations. Human genetic studies have revealed a large number of novel protein targets that cause disease via toxic gain of function. The abnormal accumulation and toxicity of these pathogenic proteins may directly cause many diseases including neurodegenerative disorders and type 2 diabetes [1.Walker L.C. LeVine H. The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly.Mol. Neurobiol. 2000; 21: 83-95Crossref PubMed Google Scholar,2.Chiti F. Dobson C.M. Protein misfolding, functional amyloid, and human disease.Annu. Rev. Biochem. 2006; 75: 333-366Crossref PubMed Scopus (5396) Google Scholar]. Traditional inhibitor identification-based drug discovery strategies are limited by the requirements of specific measurable functions of the target protein and accessible binding sites whose occupancy directly influences their function. Because of these requirements, almost all the disease-relevant scaffolding proteins, transcription factors, and other non-enzymatic proteins are essentially undruggable by the inhibitor approach. One appealing idea to address this is to enhance the global protein quality control system such that these undruggable pathogenic proteins can be corrected or eliminated. For example, remodeling the proteostasis network by small molecules targeting molecular chaperones or inducing stress responses may reduce the aggregation and toxicity of multiple disease-linked proteins in animal models (reviewed in [3.Sala A.J. et al.Shaping proteostasis at the cellular, tissue, and organismal level.J. Cell Biol. 2017; 216: 1231-1241Crossref PubMed Scopus (163) Google Scholar]). Furthermore, the induction of autophagy may provide a potential therapeutic strategy for many neurodegenerative diseases that are possibly caused by pathogenic proteins (reviewed in [4.Djajadikerta A. et al.Autophagy induction as a therapeutic strategy for neurodegenerative diseases.J. Mol. Biol. 2019; (Published online December 27, 2019. http://dx.doi.org/j.jmb.2019.1012.1035)PubMed Google Scholar]). Although these approaches have potential in treating multiple diseases, they induce global cellular changes and thus may have extensive nonspecific effects or induce strong compensatory mechanisms that offset their beneficial effects. A more specific strategy would be to selectively reduce the levels of the pathogenic proteins. One possible approach is gene therapy: gene silencing through nucleic acid-based RNA- or DNA-targeting reagents such as antisense oligonucleotides (ASOs) and genome-editing reagents, respectively [5.Schoch K.M. Miller T.M. Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases.Neuron. 2017; 94: 1056-1070Abstract Full Text Full Text PDF PubMed Scopus (205) Google Scholar,6.Maeder M.L. Gersbach C.A. Genome-editing technologies for gene and cell therapy.Mol. Ther. 2016; 24: 430-446Abstract Full Text Full Text PDF PubMed Scopus (465) Google Scholar] (Figure 1A ). Although highly promising, this approach faces some key challenges. Because they are large biomolecules, the gene therapy reagents are difficult to deliver, especially for neurological disease [7.Evers M.M. et al.Antisense oligonucleotides in therapy for neurodegenerative disorders.Adv. Drug Deliv. Rev. 2015; 87: 90-103Crossref PubMed Scopus (224) Google Scholar], and they are also prohibitively expensivei. Small molecule-induced protein degradation is an attractive alternative approach to selectively reduce the levels of pathogenic proteins, and may fulfill huge unmet medical needs. Several new approaches have been established to achieve this goal, as discussed later. Small molecules are able to induce selective degradation of the target protein of interest (POI) by adding a tag that is recognized by the degradation machinery. In 2011–2012, Crews and colleagues reported small-molecule hydrophobic tagging (HyT)-induced degradation of POIs [8.Neklesa T.K. et al.Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins.Nat. Chem. Biol. 2011; 7: 538-543Crossref PubMed Scopus (279) Google Scholar,9.Tae H.S. et al.Identification of hydrophobic tags for the degradation of stabilized proteins.ChemBioChem. 2012; 13: 538-541Crossref PubMed Scopus (66) Google Scholar]. HyT was achieved by molecules consisting of a hydrophobic fragment and a ligand binding to the POI. Thus, the HyT molecules bind to the POI and add a hydrophobic fragment to it, leading to recognition and recruitment of heat-shock proteins followed by proteasomal degradation [8.Neklesa T.K. et al.Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins.Nat. Chem. Biol. 2011; 7: 538-543Crossref PubMed Scopus (279) Google Scholar,9.Tae H.S. et al.Identification of hydrophobic tags for the degradation of stabilized proteins.ChemBioChem. 2012; 13: 538-541Crossref PubMed Scopus (66) Google Scholar]. A similar concept was illustrated by another study that used a small molecule consisting of a hydrophobic group tert-butyl carbamate-protected arginine (Boc3Arg) attached to the dihydrofolate reductase (DHFR) non-covalent binding ligand trimethoprim (TMP) to degrade DHFR [10.Long M.J. et al.Inhibitor mediated protein degradation.Chem. Biol. 2012; 19: 629-637Abstract Full Text Full Text PDF PubMed Scopus (95) Google Scholar]. The Boc3Arg-TMP molecules may recycle during the degradation process, increasing its efficacy [10.Long M.J. et al.Inhibitor mediated protein degradation.Chem. Biol. 2012; 19: 629-637Abstract Full Text Full Text PDF PubMed Scopus (95) Google Scholar]. Hedstrom and colleagues synthesized chimeric molecules by linking other POI recognition ligands to Boc3Arg and also found that they can target POIs to the 20S proteasome for degradation directly without the requirement for ATP or involvement of ubiquitination pathways [11.Shi Y. et al.Boc3Arg-linked ligands induce degradation by localizing target proteins to the 20S proteasome.ACS Chem. Biol. 2016; 11: 3328-3337Crossref PubMed Scopus (49) Google Scholar] (Figure 1). Although HyT is an interesting concept, it has not been widely used and its clinical application may be limited by Boc3Arg off-target effects [12.Coffey R.T. et al.Ubiquilin-mediated small molecule inhibition of mammalian target of rapamycin complex 1 (mTORC1) signaling.J. Biol. Chem. 2016; 291: 5221-5233Crossref PubMed Scopus (27) Google Scholar]. Currently, the prevailing approach for small molecule-induced protein degradation is the proteolysis-targeting chimera (PROTAC) technology, which provides a powerful strategy to degrade undruggable POIs and has been extensively reviewed [13.Konstantinidou M. et al.PROTACs – a game-changing technology.Expert Opin. Drug Discovery. 2019; 14: 1255-1268Crossref PubMed Scopus (107) Google Scholar, 14.Schapira M. et al.Targeted protein degradation: expanding the toolbox.Nat. Rev. Drug Discov. 2019; 18: 949-963Crossref PubMed Scopus (472) Google Scholar, 15.Sun X. et al.PROTACs: great opportunities for academia and industry.Signal Transd. Target. Ther. 2019; 4: 64Crossref PubMed Scopus (373) Google Scholar, 16.Burslem G.M. Crews C.M. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery.Cell. 2020; 181: 102-114Abstract Full Text Full Text PDF PubMed Scopus (517) Google Scholar, 17.Wang Y. et al.Degradation of proteins by PROTACs and other strategies.Acta Pharm. Sin. B. 2020; 10: 207-238Crossref PubMed Scopus (185) Google Scholar]. PROTAC molecules tether the POI to a specific E3 ligase subunit to enhance POI ubiquitination, leading to its subsequent degradation by the proteasome (Figure 1). In 2001, Crews and colleagues provided the proof-of-concept evidence for PROTAC [18.Sakamoto K.M. et al.Protacs: chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation.Proc. Natl. Acad. Sci. 2001; 98: 8554-8559Crossref PubMed Scopus (1366) Google Scholar]. They synthesized a chimeric large molecule named Protac-1 to recruit MetAP-2 to the Skp1–Cullin–F box complex, leading to ubiquitination and degradation of MetAP-2 in a dose-dependent manner. However, the MetAP-2 covalently bound moiety was a peptide, hindering further applications because its large molecule size leads to poor cellular penetration. In 2008, a cell-permeable PROTAC molecule linking the non-steroidal androgen receptor ligand (SARM) and the MDM2 ligand nutlin with a polyethylene glycol (PEG)-based linker was synthesized [19.Schneekloth A.R. et al.Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics.Bioorg. Med. Chem. Lett. 2008; 18: 5904-5908Crossref PubMed Scopus (413) Google Scholar]. This PROTAC molecule can induce the ubiquitination of the androgen receptor and its subsequent degradation by the proteasome. This PROTAC system is based on MDM2, the major E3 ligase that ubiquitinates the tumor-suppressor protein p53 [20.Fuchs S.Y. et al.Mdm2 association with p53 targets its ubiquitination.Oncogene. 1998; 17: 2543-2547Crossref PubMed Scopus (214) Google Scholar]. The nutlins family consists of small molecules that bind to the p53-binding pocket of MDM2 and thus competitively inhibit the interaction between p53 and MDM2 [21.Vassilev L.T. et al.In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.Science. 2004; 303: 844-848Crossref PubMed Scopus (3964) Google Scholar], inducing possible off-target effects. The nutlins were further improved to RG7112 [22.Vu B. et al.Discovery of RG7112: a small-molecule MDM2 Inhibitor in clinical development.ACS Med. Chem. Lett. 2013; 4: 466-469Crossref PubMed Scopus (267) Google Scholar] and RG7388 [23.Ding Q. et al.Discovery of RG7388, a potent and selective p53–MDM2 inhibitor in clinical development.J. Med. Chem. 2013; 56: 5979-5983Crossref PubMed Scopus (431) Google Scholar] that showed superior potency and selectivity. In 2010, a new PROTAC system using the cellular inhibitor of apoptosis protein 1 (cIAP1) ubiquitin ligase was established. Hashimoto and colleagues verified that a hybrid molecule coupling the cIAP1 ligand methyl bestatin and a CRABP ligand can induce degradation of CRABP-II in cells via the proteasomal pathway [24.Itoh Y. et al.Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins.J. Am. Chem. Soc. 2010; 132: 5820-5826Crossref PubMed Scopus (314) Google Scholar]. In 2015, the group of Brader established another important PROTAC system based on cereblon (CRBN) [25.Winter G.E. et al.Phthalimide conjugation as a strategy for in vivo target protein degradation.Science. 2015; 348: 1376-1381Crossref PubMed Scopus (1141) Google Scholar]. CRBN was initially identified as the primary mediator of the teratogenic activity of thalidomide by Handa and colleagues [26.Ito T. et al.Identification of a primary target of thalidomide teratogenicity.Science. 2010; 327: 1345-1350Crossref PubMed Scopus (1486) Google Scholar]. Immunomodulatory drugs (IMiDs) including thalidomide and its derivatives such as lenalidomide and pomalidomide were later utilized to treat multiple myeloma [27.Chanan-Khan A.A. et al.Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma.Blood Cancer J. 2013; 3e143Crossref PubMed Scopus (98) Google Scholar]. These IMiDs were further reported to interact with the CRBN–DNA damage binding protein 1 (DDB1) complex [28.Lopez-Girona A. et al.Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.Leukemia. 2012; 26: 2326-2335Crossref PubMed Scopus (636) Google Scholar]. Shortly thereafter a series of PROTAC molecules consisting of a CRBN-binding IMiD connected to small-molecule ligands for different POIs were designed and their degrader capability was verified [25.Winter G.E. et al.Phthalimide conjugation as a strategy for in vivo target protein degradation.Science. 2015; 348: 1376-1381Crossref PubMed Scopus (1141) Google Scholar,29.Lu J. et al.Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4.Chem. Biol. 2015; 22: 755-763Abstract Full Text Full Text PDF PubMed Scopus (786) Google Scholar,30.Lai A.C. et al.Modular PROTAC design for the degradation of oncogenic BCR–ABL.Angew. Chem. Int. Ed. Engl. 2016; 55: 807-810Crossref PubMed Scopus (450) Google Scholar]. For example, JQ1–penalidomide chimeric compounds can selectively degrade BRD4 protein via CRBN [25.Winter G.E. et al.Phthalimide conjugation as a strategy for in vivo target protein degradation.Science. 2015; 348: 1376-1381Crossref PubMed Scopus (1141) Google Scholar]. Another PROTAC system, the VHL-PROTAC system based on a HIF1-α-derived peptide, was initially introduced in 2004 [31.Schneekloth Jr., J.S. et al.Chemical genetic control of protein levels: selective in vivo targeted degradation.J. Am. Chem. Soc. 2004; 126: 3748-3754Crossref PubMed Scopus (375) Google Scholar]. In 2015, replacement of the VHL-targeting peptide by hydroxyproline-like small molecules significantly improved the affinity and specificity of the VHL-PROTAC system [32.Bondeson D.P. et al.Catalytic in vivo protein knockdown by small-molecule PROTACs.Nat. Chem. Biol. 2015; 11: 611-617Crossref PubMed Scopus (823) Google Scholar], greatly expanding its applications. Currently, although there are >600 known human E3 ligases, the established PROTAC systems rely on fewer than ten, of which the most widely used are CRBN [28.Lopez-Girona A. et al.Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.Leukemia. 2012; 26: 2326-2335Crossref PubMed Scopus (636) Google Scholar], Von Hippel Lindau (VHL) [31.Schneekloth Jr., J.S. et al.Chemical genetic control of protein levels: selective in vivo targeted degradation.J. Am. Chem. Soc. 2004; 126: 3748-3754Crossref PubMed Scopus (375) Google Scholar], cIAP [24.Itoh Y. et al.Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins.J. Am. Chem. Soc. 2010; 132: 5820-5826Crossref PubMed Scopus (314) Google Scholar], and MDM2 [19.Schneekloth A.R. et al.Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics.Bioorg. Med. Chem. Lett. 2008; 18: 5904-5908Crossref PubMed Scopus (413) Google Scholar], discussed earlier. One desirable property of PROTACs is that they are catalytically involved in multiple rounds of target protein degradation [29.Lu J. et al.Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4.Chem. Biol. 2015; 22: 755-763Abstract Full Text Full Text PDF PubMed Scopus (786) Google Scholar,32.Bondeson D.P. et al.Catalytic in vivo protein knockdown by small-molecule PROTACs.Nat. Chem. Biol. 2015; 11: 611-617Crossref PubMed Scopus (823) Google Scholar,33.Olson C.M. et al.Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.Nat. Chem. Biol. 2018; 14: 163-170Crossref PubMed Scopus (344) Google Scholar]. Therefore, the degradation induced by PROTACs is sub-stoichiometric – one PROTAC molecule is able to induce the ubiquitination and degradation of multiple POI molecules. The catalytic nature of PROTACs provides potential strong degradation power at relatively low concentration, and it can be desirable to introduce temporal and spatial control. Recent studies have developed controllable PROTACs, such as photoswitchable azobenzene-PROTACs (Azo-PROTACs) and photo-caged PROTACs (pc-PROTACs) [34.Jin Y.H. et al.Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown.J. Med. Chem. 2020; (Published online March 19, 2020. https://doi.org/10.1021/acs.jmedchem.1029b02058)Crossref Scopus (102) Google Scholar,35.Xue G. et al.Light-induced protein degradation with photocaged PROTACs.J. Am. Chem. Soc. 2019; 141: 18370-18374Crossref PubMed Scopus (191) Google Scholar]. Azo-PROTACs are light-controlled small-molecule tools for protein knockdown in cells. The light-induced configuration change can switch to the active state to induce protein degradation, and this can be reversed by light exposure in intact cells [34.Jin Y.H. et al.Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown.J. Med. Chem. 2020; (Published online March 19, 2020. https://doi.org/10.1021/acs.jmedchem.1029b02058)Crossref Scopus (102) Google Scholar]. For pc-PROTACs, photo-removable blocking groups were added to a degrader of Brd4, and the resulting molecule showed potent degradation activity in live cells only after light irradiation [35.Xue G. et al.Light-induced protein degradation with photocaged PROTACs.J. Am. Chem. Soc. 2019; 141: 18370-18374Crossref PubMed Scopus (191) Google Scholar]. Although the PROTAC field is booming, several potential limitations have been identified: PROTAC molecules often have high molecular weight (>800 Da) and a relatively high polar surface area, likely leading to low solubility, poor cell permeability, and low oral bioavailability and blood–brain barrier penetration. The effects of PROTAC are dependent on specific E3 ligase subunits and thus are influenced by their expression, limiting their application to particular cell types. The dependence on specific E3 ligase subunits may also cause cancer cell resistance following chronic PROTAC treatment [36.Zhang L. et al.Acquired resistance to BET-PROTACs (proteolysis-targeting chimeras) caused by genomic alterations in core components of E3 ligase complexes.Mol. Cancer Ther. 2019; 18: 1302-1311Crossref PubMed Scopus (169) Google Scholar]. Finally, PROTAC molecules induce POI degradation via the proteasome, which has limited ability to degrade proteins with expanded repeat sequences, protein aggregates, and other non-protein molecules [37.Wong E. Cuervo A.M. Integration of clearance mechanisms: the proteasome and autophagy.Cold Spring Harb. Perspect. Biol. 2010; 2a006734Crossref PubMed Scopus (246) Google Scholar]. As discussed earlier, although the PROTAC technology is extremely promising, its dependence on the expression of specific E3 ligases and the proteasomal pathway may limit its potential applications for particular cell types or proteasome-resistant proteins. Encouragingly, novel concepts have emerged very recently regarding the lysosomal degradation pathway – a second major pathway of degradation that is independent of the proteasome [38.Tooze S.A. et al.Endocytosis and autophagy: exploitation or cooperation?.Cold Spring Harb. Perspect. Biol. 2014; 6a018358Crossref PubMed Scopus (151) Google Scholar]. The lysosomal degradation pathway includes the endosome/lysosome pathway and the autophagy pathway (reviewed in [39.Pillay C.S. et al.Endolysosomal proteolysis and its regulation.Biochem. J. 2002; 363: 417-429Crossref PubMed Scopus (282) Google Scholar,40.Kundu M. Thompson C.B. Autophagy: basic principles and relevance to disease.Annu. Rev. Pathol. 2008; 3: 427-455Crossref PubMed Scopus (474) Google Scholar]). The endosome/lysosome pathway involves sequential processing by several membrane-bound intracellular compartments: the endocytosed material is incorporated and proceeds through early endosomes, endosome carrier vesicles, late endosomes, and the lysosome for subsequent hydrolysis [39.Pillay C.S. et al.Endolysosomal proteolysis and its regulation.Biochem. J. 2002; 363: 417-429Crossref PubMed Scopus (282) Google Scholar]. The autophagy pathway starts with an isolated membrane structure called a phagophore, which is derived from lipid bilayer with lipidated LC3 proteins [41.Kabeya Y. et al.LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.EMBO J. 2000; 19: 5720-5728Crossref PubMed Scopus (5745) Google Scholar]. This phagophore expands to engulf intracellular cargoes (autophagy substrates), including proteins and other biomolecules or even organelles, thereby sequestering them in a double-membrane vesicle called the autophagosome [40.Kundu M. Thompson C.B. Autophagy: basic principles and relevance to disease.Annu. Rev. Pathol. 2008; 3: 427-455Crossref PubMed Scopus (474) Google Scholar]. The loaded autophagosome matures through fusion with the lysosome, leading to cargo degradation. Thus, both the endosome/lysosome pathway and the autophagy pathway are able to degrade target material, and new concepts have been developed to harness each of these pathways for selective degradation. The LYTAC (lysosome targeting chimera) technology is a promising strategy to exploit the endosome/lysosome pathway to degrade POIs, currently published as a preprint paper without peer review [42.Banik S. et al.Lysosome targeting Chimeras (LYTACs) for the degradation of secreted and membrane proteins.ChemRxiv. 2019; (Published online November 20, 2019. http://dx.doi.org/10.26434/chemrxiv.7927061)Google Scholar]. Excitingly, LYTAC molecules may work on extracellular proteins as well as on membrane-bound proteins such as EGFR [42.Banik S. et al.Lysosome targeting Chimeras (LYTACs) for the degradation of secreted and membrane proteins.ChemRxiv. 2019; (Published online November 20, 2019. http://dx.doi.org/10.26434/chemrxiv.7927061)Google Scholar]. These types of proteins are typically resistant to PROTAC, which mainly targets intracellular proteins. A LYTAC molecule consists of an antibody to a specific POI, and a 20- or 90-mer of mannose-6-phosphate (M6P) is covalently attached to this antibody. M6P is a glycan that targets proteins for degradation by binding to the cation-independent M6P receptor (CI-M6PR) [42.Banik S. et al.Lysosome targeting Chimeras (LYTACs) for the degradation of secreted and membrane proteins.ChemRxiv. 2019; (Published online November 20, 2019. http://dx.doi.org/10.26434/chemrxiv.7927061)Google Scholar]. Thus, M6P-conjugated antibodies, namely the LYTAC molecules, are recognized by this endogenous system for lysosomal degradation of glycosylated proteins, and bring glycans together with the POI to the lysosome for degradation. In some cases the M6P-conjugated antibodies can be replaced by CI-M6PR polypeptide ligands conjugated to a small molecule that binds to the POI. The authors confirmed that a polypeptide with multiple ligands for CI-M6PR attached to biotin (a high-affinity avidin-binding molecule) targets the extracellular NeutrAvidin protein to endosomes and lysosomes [42.Banik S. et al.Lysosome targeting Chimeras (LYTACs) for the degradation of secreted and membrane proteins.ChemRxiv. 2019; (Published online November 20, 2019. http://dx.doi.org/10.26434/chemrxiv.7927061)Google Scholar]. The advantage of the LYTAC technology is that it enables degradation of both extracellular and membrane-associated POIs, and it utilizes a ubiquitously expressed endogenous degradation pathway. The major limitation is that LYTAC molecules are relatively large, and thus lose the desired properties of small-molecule drugs. The antibody or polypeptide nature of the molecules may also induce immune responses [43.Van Regenmortel M.H. Antigenicity and immunogenicity of synthetic peptides.Biologicals. 2001; 29: 209-213Crossref PubMed Scopus (162) Google Scholar]. The LYTAC technology targets extracellular and/or membrane POIs to the endosome/lysosome pathway, and is not applicable to cytosolic proteins. However, these can be targets for autophagy, and autophagy-targeting degrader technologies are highly desirable for cytosolic POIs, especially those resistant to PROTAC molecules. Although there are several different types of autophagy, the term typically refers to macroautophagy, a multistep cellular process in which cargo proteins are engulfed into autophagosomes formed by intracellular double membranes that contain lipidated LC3 proteins [41.Kabeya Y. et al.LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.EMBO J. 2000; 19: 5720-5728Crossref PubMed Scopus (5745) Google Scholar]. Autophagy receptors such as SQSTM1/p62 may recognize Lys63 (K63) polyubiquitinated protein cargoes and shuttle them to autophagosomes for subsequent clearance [44.Kirkin V. et al.A role for ubiquitin in selective autophagy.Mol. Cell. 2009; 34: 259-269Abstract Full Text Full Text PDF PubMed Scopus (1033) Google Scholar], and this process is referred to as 'selective autophagy' [45.Johansen T. Lamark T. Selective autophagy mediated by autophagic adapter proteins.Autophagy. 2011; 7: 279-296Crossref PubMed Scopus (1377) Google Scholar,46.Filimonenko M. et al.The selective macroautophagic degradation of aggregated proteins requires the PI3P-binding protein Alfy.Mol. Cell. 2010; 38: 265-279Abstract Full Text Full Text PDF PubMed Scopus (355) Google Scholar]. Two independent new degrader technologies harnessing the autophagy pathway have been reported very recently. The autophagy-targeting chimera (AUTAC) system has a similar design to the PROTAC technology [47.Takahashi D. et al.AUTACs: cargo-specific degraders using selective autophagy.Mol. Cell. 2019; 76: 797-810Abstract Full Text Full Text PDF PubMed Scopus (298) Google Scholar]. Both AUTAC and PROTAC molecules function via ubiquitination. However, instead of tethering the POIs to an E3 ligase subunit and triggering K48 polyubiquitination, AUTAC molecules trigger K63 polyubiquitination, which is recognized by the selective autophagy pathway, leading to degradation of the target POI. An AUTAC molecule contains a degradation tag (guanine derivative) and a ligand of the POI to provide target specificity. The degradation tag mimics S-guanylation, a post-translational modification of Cys-cGMP adducts formed by treatment with 8-nitro-cGMP or a similar compound [48.Sawa T. et al.Protein S-guanylation by the biological signal 8-nitroguanosine 3',5'-cyclic monophosphate.Nat. Chem. Biol. 2007; 3: 727-735Crossref PubMed Scopus (233) Google Scholar]. The authors suggest that S-guanylation is a standalone tag that marks the substrate protein for selective autophagy by inducing K63 polyubiquitination [47.Takahashi D. et al.AUTACs: cargo-specific degraders using selective autophagy.Mol. Cell. 2019; 76: 797-810Abstract Full Text Full Text PDF PubMed Scopus (298) Google Scholar]. The authors reported encouraging results that AUTAC molecules are capable of degrading POIs as well as cellular organelles such as damaged mitochondria. The design of AUTAC cleverly utilizes a process that defends cells against invading group A Streptococcus [49.Nakagawa I. et al.Autophagy defends cells against invading group A Streptococcus.Science. 2004; 306: 1037-1040Crossref PubMed Scopus (979) Google Scholar]. AUTAC molecules function through a complex multiple-step process that needs to be further clarified. In particular, the molecular mechanism mediating S-guanylation-triggered K63 ubiquitination of POIs needs to be elucidated, and the efficiency and potential off-target effects of this pathway need to be determined. This will clarify which proteins are required for the AUTAC system, how the AUTAC system is influenced by each mediator, and whether exploiting this pathway may cause changes to other cellular functions. In addition, whether AUTAC molecules influence the selective autophagy process per se and whether they are functional in vivo need to be investigated. The concept of autophagosome-tethering compound (ATTEC) illustrates a more direct strategy to harness autophagy to degrade POIs [50.Li Z. et al.ATTEC: a potential new approach to target proteinopathies.Autophagy. 2020; 16: 185-187Crossr